Group 1:20µg vaccine

2 trials

Sponsors

Shulan (Hangzhou) Hospital

Conditions

SARS-CoV-2 (COVID-19)

Phase 1

A Randomized, Observer-blinded, Placebo-Controlled, Dose Escalation Phase 1 Clinical Study to Evaluate the Safety and Preliminary Immunogenicity of SYS6006 (SARS-CoV-2 mRNA Vaccine) in Healthy People Aged 60 years and more

Active, not recruitingChiCTR2200059104

Shulan (Hangzhou) HospitalSARS-CoV-2 (COVID-19)

Start: 2022-04-26Updated: 2024-02-11

A Randomized, Observer-blinded, Placebo-Controlled, Dose Escalation Phase 1 Clinical Study to Evaluate the Safety and Preliminary Immunogenicity of SYS6006 (SARS-CoV-2 mRNA Vaccine) in Healthy People Aged 18-59

Active, not recruitingChiCTR2200059103

Shulan (Hangzhou) HospitalSARS-CoV-2 (COVID-19)

Start: 2022-04-26Updated: 2024-02-11

Related Papers

Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials

Human Vaccines & Immunotherapeutics2023-12-159 citations